Short answer
Arcus Biosciences, Inc. (RCUS) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3M (down 50.0% year over year) with net income of −$128M.
Q3 2026 key financials · XBRL
- Revenue
- $3M
- −50.0% YoY · −90.9% QoQ
- Net income
- −$128M
- +5.2% YoY · −40.7% QoQ
- Operating margin
- -4366.7%
- EPS (diluted)
- −$1.00
- +23.1% YoY · −38.9% QoQ
Source: XBRL data from the Arcus Biosciences, Inc. (RCUS) Q3 2026 10-Q on SEC EDGAR. USD.
Arcus Biosciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue decline, exact quarterly dollar amounts obscured in filing table, down 65% YoY overall
- Net loss $128M vs $135M YoY, operating loss $131M vs $142M
- Best program: casdatifan plus cabozantinib, median PFS 14.5 months and cORR 44%
- Worst program: domvanalimab, PACIFIC-8 Phase 3 discontinued in August 2026
- Operating cash use $345M vs $362M, October equity offering gross proceeds approximately $288M, runway into 2029
Risk Factors
- Newly triggered compliance risk: U.S. BIOSECURE Act enacted December 2025 could restrict sole zimberelimab manufacturer WuXi Biologics
- Most material operational update: etrumadenant development paused in third-line metastatic colorectal cancer to prioritize late-stage programs
- Regulatory risk: FDA disruptions from funding shortages, staffing limitations, and policy changes could delay reviews and approvals
- Competitive risk: Phase 3 STAR-221 discontinued after December 2025 interim analysis showed no benefit versus standard of care
- Financial risk: $694 million cash, equivalents, and marketable securities funds planned operations into 2029; additional capital may still be required
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcus Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.